Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
GlobalData on MSN2d
AbbVie and Simcere Zaiming link to develop trispecific antibodyThe humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...
AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, ...
Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...
NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...
NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback